Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

SORT1-targeted docetaxel TH1902

A peptide-drug conjugate composed of the second-generation taxane docetaxel and the sortilin (SORT1)-targeting peptide TH19P01, with potential antineoplastic activity. Upon administration of SORT1-targeted docetaxel TH1902, the TH19P01 moiety targets and binds to SORT1 expressed on tumor cells. Upon internalization, docetaxel binds to and stabilizes the beta-tubulin subunit, thereby inhibiting microtubule disassembly which results in cell-cycle arrest at the G2/M phase and cell death. SORT1 is overexpressed in a variety of cancers and plays an important role in protein internalization, sorting and trafficking.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:docetaxel-TH19P01 conjugate TH1902
sortilin-targeted docetaxel TH1902
Code name:TH 1902
TH-1902
TH1902
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search